By Elaine Chen June 5, 2023 ADOBE GLP-1s, a class of drugs including Ozempic and Wegovy that have become widely popular for treating obesity and diabetes, are also being studied for NASH, a form of fatty liver disease. But a new small study suggests GLP-1s may not dominate the disease area as they have others. Akero Therapeutics tested...
